Raymond James & Associates Raises Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)

Raymond James & Associates boosted its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) by 0.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 74,097 shares of the company’s stock after purchasing an additional 565 shares during the quarter. Raymond James & Associates owned approximately 0.18% of Cassava Sciences worth $1,668,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Cassava Sciences by 4.7% during the 2nd quarter. BlackRock Inc. now owns 2,746,908 shares of the company’s stock worth $67,354,000 after acquiring an additional 124,231 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Cassava Sciences by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,268,566 shares of the company’s stock worth $37,749,000 after acquiring an additional 18,907 shares in the last quarter. State Street Corp boosted its position in shares of Cassava Sciences by 6.5% during the 1st quarter. State Street Corp now owns 1,058,949 shares of the company’s stock worth $25,542,000 after acquiring an additional 64,903 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cassava Sciences by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 803,306 shares of the company’s stock worth $19,697,000 after acquiring an additional 44,350 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Cassava Sciences by 0.8% during the 3rd quarter. Northern Trust Corp now owns 373,634 shares of the company’s stock worth $6,217,000 after acquiring an additional 2,996 shares in the last quarter. Hedge funds and other institutional investors own 38.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $124.00 price objective on shares of Cassava Sciences in a research report on Tuesday, March 5th.

Cassava Sciences Stock Performance

NASDAQ:SAVA opened at $21.19 on Friday. The stock has a 50-day simple moving average of $21.83 and a 200-day simple moving average of $19.70. The stock has a market cap of $916.47 million, a P/E ratio of -9.13 and a beta of -0.45. Cassava Sciences, Inc. has a 1 year low of $12.32 and a 1 year high of $32.10.

Cassava Sciences (NASDAQ:SAVA) last announced its earnings results on Wednesday, February 28th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). On average, equities research analysts predict that Cassava Sciences, Inc. will post -2.01 EPS for the current year.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.